Cargando…

Inflammatory Markers and Poor Outcome after Stroke: A Prospective Cohort Study and Systematic Review of Interleukin-6

BACKGROUND: The objective of this study was to determine whether: (a) markers of acute inflammation (white cell count, glucose, interleukin-6, C-reactive protein, and fibrinogen) are associated with poor outcome after stroke and (b) the addition of markers to previously validated prognostic models i...

Descripción completa

Detalles Bibliográficos
Autores principales: Whiteley, William, Jackson, Caroline, Lewis, Steff, Lowe, Gordon, Rumley, Ann, Sandercock, Peter, Wardlaw, Joanna, Dennis, Martin, Sudlow, Cathie
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730573/
https://www.ncbi.nlm.nih.gov/pubmed/19901973
http://dx.doi.org/10.1371/journal.pmed.1000145
_version_ 1782170906263552000
author Whiteley, William
Jackson, Caroline
Lewis, Steff
Lowe, Gordon
Rumley, Ann
Sandercock, Peter
Wardlaw, Joanna
Dennis, Martin
Sudlow, Cathie
author_facet Whiteley, William
Jackson, Caroline
Lewis, Steff
Lowe, Gordon
Rumley, Ann
Sandercock, Peter
Wardlaw, Joanna
Dennis, Martin
Sudlow, Cathie
author_sort Whiteley, William
collection PubMed
description BACKGROUND: The objective of this study was to determine whether: (a) markers of acute inflammation (white cell count, glucose, interleukin-6, C-reactive protein, and fibrinogen) are associated with poor outcome after stroke and (b) the addition of markers to previously validated prognostic models improves prediction of poor outcome. METHODS AND FINDINGS: We prospectively recruited patients between 2002 and 2005. Clinicians assessed patients and drew blood for inflammatory markers. Patients were followed up by postal questionnaire for poor outcome (a score of>2 on the modified Rankin Scale) and death through the General Register Office (Scotland) at 6 mo. We performed a systematic review of the literature and meta-analysis of the association between interleukin-6 and poor outcome after stroke to place our study in the context of previous research. We recruited 844 patients; mortality data were available in 844 (100%) and functional outcome in 750 (89%). After appropriate adjustment, the odds ratios for the association of markers and poor outcome (comparing the upper and the lower third) were interleukin-6, 3.1 (95% CI: 1.9–5.0); C-reactive protein, 1.9 (95% CI: 1.2–3.1); fibrinogen, 1.5 (95% CI: 1.0–2.36); white cell count, 2.1 (95% CI: 1.3–3.4); and glucose 1.3 (95% CI: 0.8–2.1). The results for interleukin-6 were similar to other studies. However, the addition of inflammatory marker levels to validated prognostic models did not materially improve model discrimination, calibration, or reclassification for prediction of poor outcome after stroke. CONCLUSIONS: Raised levels of markers of the acute inflammatory response after stroke are associated with poor outcomes. However, the addition of these markers to a previously validated stroke prognostic model did not improve the prediction of poor outcome. Whether inflammatory markers are useful in prediction of recurrent stroke or other vascular events is a separate question, which requires further study. Please see later in the article for the Editors' Summary
format Text
id pubmed-2730573
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-27305732009-09-08 Inflammatory Markers and Poor Outcome after Stroke: A Prospective Cohort Study and Systematic Review of Interleukin-6 Whiteley, William Jackson, Caroline Lewis, Steff Lowe, Gordon Rumley, Ann Sandercock, Peter Wardlaw, Joanna Dennis, Martin Sudlow, Cathie PLoS Med Research Article BACKGROUND: The objective of this study was to determine whether: (a) markers of acute inflammation (white cell count, glucose, interleukin-6, C-reactive protein, and fibrinogen) are associated with poor outcome after stroke and (b) the addition of markers to previously validated prognostic models improves prediction of poor outcome. METHODS AND FINDINGS: We prospectively recruited patients between 2002 and 2005. Clinicians assessed patients and drew blood for inflammatory markers. Patients were followed up by postal questionnaire for poor outcome (a score of>2 on the modified Rankin Scale) and death through the General Register Office (Scotland) at 6 mo. We performed a systematic review of the literature and meta-analysis of the association between interleukin-6 and poor outcome after stroke to place our study in the context of previous research. We recruited 844 patients; mortality data were available in 844 (100%) and functional outcome in 750 (89%). After appropriate adjustment, the odds ratios for the association of markers and poor outcome (comparing the upper and the lower third) were interleukin-6, 3.1 (95% CI: 1.9–5.0); C-reactive protein, 1.9 (95% CI: 1.2–3.1); fibrinogen, 1.5 (95% CI: 1.0–2.36); white cell count, 2.1 (95% CI: 1.3–3.4); and glucose 1.3 (95% CI: 0.8–2.1). The results for interleukin-6 were similar to other studies. However, the addition of inflammatory marker levels to validated prognostic models did not materially improve model discrimination, calibration, or reclassification for prediction of poor outcome after stroke. CONCLUSIONS: Raised levels of markers of the acute inflammatory response after stroke are associated with poor outcomes. However, the addition of these markers to a previously validated stroke prognostic model did not improve the prediction of poor outcome. Whether inflammatory markers are useful in prediction of recurrent stroke or other vascular events is a separate question, which requires further study. Please see later in the article for the Editors' Summary Public Library of Science 2009-09-08 /pmc/articles/PMC2730573/ /pubmed/19901973 http://dx.doi.org/10.1371/journal.pmed.1000145 Text en Whiteley et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Whiteley, William
Jackson, Caroline
Lewis, Steff
Lowe, Gordon
Rumley, Ann
Sandercock, Peter
Wardlaw, Joanna
Dennis, Martin
Sudlow, Cathie
Inflammatory Markers and Poor Outcome after Stroke: A Prospective Cohort Study and Systematic Review of Interleukin-6
title Inflammatory Markers and Poor Outcome after Stroke: A Prospective Cohort Study and Systematic Review of Interleukin-6
title_full Inflammatory Markers and Poor Outcome after Stroke: A Prospective Cohort Study and Systematic Review of Interleukin-6
title_fullStr Inflammatory Markers and Poor Outcome after Stroke: A Prospective Cohort Study and Systematic Review of Interleukin-6
title_full_unstemmed Inflammatory Markers and Poor Outcome after Stroke: A Prospective Cohort Study and Systematic Review of Interleukin-6
title_short Inflammatory Markers and Poor Outcome after Stroke: A Prospective Cohort Study and Systematic Review of Interleukin-6
title_sort inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730573/
https://www.ncbi.nlm.nih.gov/pubmed/19901973
http://dx.doi.org/10.1371/journal.pmed.1000145
work_keys_str_mv AT whiteleywilliam inflammatorymarkersandpooroutcomeafterstrokeaprospectivecohortstudyandsystematicreviewofinterleukin6
AT jacksoncaroline inflammatorymarkersandpooroutcomeafterstrokeaprospectivecohortstudyandsystematicreviewofinterleukin6
AT lewissteff inflammatorymarkersandpooroutcomeafterstrokeaprospectivecohortstudyandsystematicreviewofinterleukin6
AT lowegordon inflammatorymarkersandpooroutcomeafterstrokeaprospectivecohortstudyandsystematicreviewofinterleukin6
AT rumleyann inflammatorymarkersandpooroutcomeafterstrokeaprospectivecohortstudyandsystematicreviewofinterleukin6
AT sandercockpeter inflammatorymarkersandpooroutcomeafterstrokeaprospectivecohortstudyandsystematicreviewofinterleukin6
AT wardlawjoanna inflammatorymarkersandpooroutcomeafterstrokeaprospectivecohortstudyandsystematicreviewofinterleukin6
AT dennismartin inflammatorymarkersandpooroutcomeafterstrokeaprospectivecohortstudyandsystematicreviewofinterleukin6
AT sudlowcathie inflammatorymarkersandpooroutcomeafterstrokeaprospectivecohortstudyandsystematicreviewofinterleukin6